AR055100A1 - Benzimidazoles triciclicos y su uso como moduladores de receptores metabotropicos de glutamato - Google Patents
Benzimidazoles triciclicos y su uso como moduladores de receptores metabotropicos de glutamatoInfo
- Publication number
- AR055100A1 AR055100A1 ARP060103273A ARP060103273A AR055100A1 AR 055100 A1 AR055100 A1 AR 055100A1 AR P060103273 A ARP060103273 A AR P060103273A AR P060103273 A ARP060103273 A AR P060103273A AR 055100 A1 AR055100 A1 AR 055100A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkylene
- group
- nr6r7
- alkyl
- independently selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Abstract
Reivindicacion 1: Un compuesto de formula (1): en donde A se selecciona del grupo formado por CR8R9, NR5, O, S, SO y SO2, B se selecciona del grupo formado por CH y N; D se selecciona del grupo formado por NH, N-C1-6-alquilo, y -(CR5R6)z-, en donde uno de los grupos -CR5R6- se puede reemplazar por -C(O)-, NH, o NC1-6-alquilo; L se selecciona del grupo formado por un enlace directo y -(CR5R6)w-, en donde cuando L es -(CR5R6)w; (i) B-L pueden ser insaturados, o dos átomos de carbono adyacentes pueden formar parte de un anillo ciclopropilo; o (ji) uno o dos grupos CR5R6 se puede reemplazar con O, S, o NR5; el resto de formula (2) representa un anillo seleccionado entre el grupo formado por azetidina y un anillo de 5 a 7 miembros, que pueden ser insaturados, en donde el anillo puede estar sustituido por uno o más R4; R1en cada caso, se selecciona del grupo formado por H, F, Cl, Br, I, OH, CN, nitro, C1-6-alquilo, OC1-6-alquilo, C1-6-alquilhalo, OC1-6-alquilhalo, C2-6-alquenilo, OC2-6-alquenilo, C2-6-alquinilo, OC2-6-alquinilo, C3-8-cicloalquilo, C1-6-alquilen-C3-8-cicloalquilo, OC0-6- alquilen-C3-8-cicloalquilo, arilo, heteroarilo, C1-6-alquilenoarilo, C1-6-alquilenoheteroarilo, OC1-6- alquilenoarilo, OC1-6- alquilenoheteroarilo, C1-6-alquilenoheterocicloalquilo, (CO) R5, (CO)OR5, C1-6-alquilenoOR5, OC2-6-alquilenoOR5, C1-6-alquileno (CO)R5, OC1-6-alquileno(CO)R5, C1-6-alquilenociano, OC2-6-alquilenociano, C0-6-alquilenoNR6R7, OC2-6-alquilenoNR6R7, C1-6- alquileno(CO)NR6R7, OC1-6-alquileno(CO) NR6R7, C0-6-alquilenoNR6(CO)R7, OC2-6-alquilenoNR6(CO)R7, C0-6-alquilenoNR6(CO)NR6R7, C0-6-alquilenoSO2R5, OC2-6-alquilenoSO2R5, C0--6-alquileno (SO2) NR6R7, OC2-6-alquileno (SO2)NR6R7, C0-6-alquilenoNR6 (SO2)R7, OC2-6-alquilenoNR6 (SO2)R7', C0-6- alquilenoNR6(SO2)NR6R7, OC2-6-alquilenoNR6(SO2)NR6R7, (CO)NR6R7 y SO3R5, en donde cualquier grupo cíclico puede estar también sustituido con uno o más grupos R2; R2 y R4, en cada caso, se seleccionan en forma independiente entre el grupo formado por H, F, Cl, Br, I, CN, nitro, hidroxi, oxo, C1-6-alquilo, OC1-6-alquilo, C1-6-alquilhalo, OC1-6-alquilhalo y C0-6-alquilenoNR5R6; R3 es un sistema de anillo de 5 a 12 miembros que es opcionalmente sustituido por hasta tres grupos R1, en donde el sistema de anillo puede contener uno o más heteroátomos seleccionados en forma independiente entre el grupo formado por N, O y S; R5 se selecciona del grupo formado por H, C1-6-alquilo, arilo, C3-8- cicloalquilo, C1-6-alquilenoarilo y C1-6-alquilen-C3-8-cicloalquilo, en donde cualquier grupo cíclico puede estar también sustituido con uno o más grupos R2 seleccionados en forma independiente; R6 y R7 se seleccionan en forma independiente entre el grupo formado por H, y C1-6- alquilo; R8 y R9 se seleccionan en forma independiente entre el grupo formado por H, -O-(CH2)2-O- y -O-(CH2)3-O-; m y n son enteros seleccionados en forma independiente entre el grupo formado por 0, 1, 2, 3 y 4, con la salvedad de que m y n no pueden ser simultáneamente 0; x y y son enteros seleccionados en forma independiente entre el grupo formado por 1, 2, y 3; y w y z'. son enteros seleccionados en forma independiente entre el grupo formado por 1, 2, 3, 4, 5, y 6; o una sal aceptable para uso farmacéutico, hidrato, solvato, isoforma, tautomero, isomero optico, o combinacion de los mismos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70547105P | 2005-08-05 | 2005-08-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR055100A1 true AR055100A1 (es) | 2007-08-08 |
Family
ID=37607094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060103273A AR055100A1 (es) | 2005-08-05 | 2006-07-28 | Benzimidazoles triciclicos y su uso como moduladores de receptores metabotropicos de glutamato |
Country Status (17)
Country | Link |
---|---|
US (2) | US20070032469A1 (es) |
EP (1) | EP1912989A2 (es) |
JP (1) | JP2009503069A (es) |
KR (1) | KR20080035576A (es) |
CN (1) | CN101268077A (es) |
AR (1) | AR055100A1 (es) |
AU (1) | AU2006279034A1 (es) |
BR (1) | BRPI0614168A2 (es) |
CA (1) | CA2616020A1 (es) |
EC (1) | ECSP088128A (es) |
IL (1) | IL188809A0 (es) |
MX (1) | MX2008001152A (es) |
NO (1) | NO20080475L (es) |
RU (1) | RU2008101923A (es) |
TW (1) | TW200745112A (es) |
UY (1) | UY29710A1 (es) |
WO (1) | WO2007018998A2 (es) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE529246C2 (sv) * | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
WO2007065655A1 (en) * | 2005-12-07 | 2007-06-14 | Neurosearch Sweden Ab | Disubstituted phenylpiperidines as modulators of cortical catecholaminergic neurotransmission |
AR059898A1 (es) * | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
TW200845978A (en) * | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
EP2150244A1 (en) * | 2007-04-23 | 2010-02-10 | House Ear Institute | Treatment and/or prevention of presbycusis by modulation of metabotropic glutamate receptor 7 |
CN101801951B (zh) * | 2007-09-14 | 2013-11-13 | 杨森制药有限公司 | 1’,3’-二取代的-4-苯基-3,4,5,6-四氢-2h,1’h-[1,4’]二吡啶-2’-酮 |
TW200927731A (en) | 2007-09-14 | 2009-07-01 | Ortho Mcneil Janssen Pharm | 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones |
KR20100065191A (ko) | 2007-09-14 | 2010-06-15 | 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 | 1,3-이치환된 4-(아릴-x-페닐)-1h-피리딘-2-온 |
ES2637794T3 (es) * | 2007-11-14 | 2017-10-17 | Janssen Pharmaceuticals, Inc. | Derivados de imidazo[1,2-A]piridina y su uso como moduladores alostéricos positivos de receptores MGLUR2 |
DE102008022221A1 (de) | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
AU2009246626A1 (en) * | 2008-05-15 | 2009-11-19 | Merck Sharp & Dohme Corp. | Oxazolobenzimidazole derivatives |
WO2009140166A2 (en) * | 2008-05-15 | 2009-11-19 | Merck & Co., Inc. | Oxazolobenzimidazole derivatives |
CA2724449C (en) * | 2008-05-29 | 2017-05-30 | Albany Molecular Research, Inc. | 5-ht3 receptor modulators, methods of making, and use thereof |
US20110171134A1 (en) * | 2008-06-25 | 2011-07-14 | Iskandar Bermans J | (6s)-5-methyltetrahydrofolic acid for therapy of tissue injury |
RU2510396C2 (ru) | 2008-09-02 | 2014-03-27 | Янссен Фармасьютикалз, Инк. | 3-азабицикло[3.1.0]гексильные производные в качестве модуляторов метаботропных глутаматных рецепторов |
JP2012503658A (ja) * | 2008-09-26 | 2012-02-09 | メルク・シャープ・エンド・ドーム・コーポレイション | オキサゾロベンゾイミダゾール誘導体 |
BRPI0920354A2 (pt) | 2008-10-16 | 2017-06-27 | Addex Pharmaceuticals Sa | derivados de indol e benzomorfolina como moduladores de receptores de glutamato metabotrópicos |
AU2009319387B2 (en) | 2008-11-28 | 2012-05-10 | Addex Pharma S.A. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
JP5707390B2 (ja) | 2009-05-12 | 2015-04-30 | ジャンセン ファーマシューティカルズ, インコーポレイテッド | 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体の正のアロステリック調節因子としてのその使用 |
RS53075B (en) | 2009-05-12 | 2014-04-30 | Janssen Pharmaceuticals Inc. | 1,2,4-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS |
US8541404B2 (en) * | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
EP2649069B1 (en) | 2010-11-08 | 2015-08-26 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
EP2661435B1 (en) | 2010-11-08 | 2015-08-19 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
EP2643320B1 (en) | 2010-11-08 | 2015-03-04 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
US9381187B2 (en) | 2011-02-16 | 2016-07-05 | Paloma Pharmaceuticals, Inc. | Radiation countermeasure agents |
JP6205354B2 (ja) | 2011-07-06 | 2017-09-27 | ギリアード サイエンシーズ, インコーポレイテッド | Hivの処置のための化合物 |
GB201220157D0 (en) * | 2012-11-08 | 2012-12-26 | Selvita Sa | Substitute tricyclic benzimidazoles as kinase inhibitors |
CN102964292A (zh) * | 2012-11-26 | 2013-03-13 | 盛世泰科生物医药技术(苏州)有限公司 | 4-(2-(三氟甲氧基)苯基)哌啶的合成 |
BR112015022942B1 (pt) * | 2013-03-15 | 2022-02-22 | Incyte Holdings Corporation | Compostos heterocíciclos tricíclicos, método para inibir proteína bet in vitro e composição farmacêutica compreendendo os referidos compostos |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
JP2016523964A (ja) | 2013-07-08 | 2016-08-12 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Betタンパク質阻害剤としての三環式複素環 |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
KR101672096B1 (ko) * | 2013-09-30 | 2016-11-02 | 주식회사 엘지화학 | 헤테로환 화합물 및 이를 포함하는 유기 발광 소자 |
WO2015081189A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
WO2015081203A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
DK3431106T3 (da) | 2014-01-21 | 2021-03-15 | Janssen Pharmaceutica Nv | Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse |
ES2860298T3 (es) | 2014-01-21 | 2021-10-04 | Janssen Pharmaceutica Nv | Combinaciones que comprenden moduladores alostéricos positivos del receptor glutamatérgico metabotrópico de subtipo 2 y su uso |
US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
WO2015154047A1 (en) * | 2014-04-03 | 2015-10-08 | Restorgenex Corporation | Novel methods |
NZ763740A (en) | 2014-04-23 | 2023-06-30 | Incyte Holdings Corp | 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins |
JP6579549B2 (ja) | 2014-05-16 | 2019-09-25 | 塩野義製薬株式会社 | Hiv複製阻害作用を有する3環性複素環誘導体 |
JP6599979B2 (ja) * | 2014-09-15 | 2019-10-30 | インサイト・コーポレイション | Betタンパク質阻害剤として用いるための三環式複素環化合物 |
CA2987384A1 (en) * | 2015-05-29 | 2016-12-08 | Shionogi & Co., Ltd. | Nitrogen-containing tricyclic derivative having hiv replication inhibitory activity |
US10065970B2 (en) | 2015-09-08 | 2018-09-04 | Genentech, Inc. | Tricyclic PI3K inhibitor compounds and methods of use |
CA2998375A1 (en) | 2015-09-17 | 2017-03-23 | Marvin J. Miller | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection |
WO2017075377A1 (en) | 2015-10-29 | 2017-05-04 | Incyte Corporation | Amorphous solid form of a bet protein inhibitor |
FI3472157T3 (fi) | 2016-06-20 | 2023-06-01 | Incyte Corp | Bet-inhibiittorin kiteisiä kiinteitä muotoja |
KR102180740B1 (ko) | 2016-08-19 | 2020-11-20 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물 |
CA3089590C (en) | 2018-02-15 | 2022-12-06 | Gilead Sciences, Inc. | Pyridine derivatives and their use for treating hiv infection |
AR114631A1 (es) | 2018-02-16 | 2020-09-30 | Gilead Sciences Inc | Métodos e intermedios para preparar compuestos de piridina |
WO2020006432A1 (en) | 2018-06-28 | 2020-01-02 | Eternity Bioscience Inc. | Fused tricyclic heterocycle compounds and therapeutic uses thereof |
KR20210033492A (ko) | 2018-07-16 | 2021-03-26 | 길리애드 사이언시즈, 인코포레이티드 | Hiv의 치료를 위한 캡시드 억제제 |
WO2020124059A1 (en) * | 2018-12-14 | 2020-06-18 | Eternity Bioscience Inc. | Tricyclic compounds as sting agonists, and preparation methods and medicinal uses thereof |
WO2020151682A1 (zh) * | 2019-01-23 | 2020-07-30 | 成都先导药物开发股份有限公司 | 一种大环类免疫调节剂 |
CA3133070A1 (en) * | 2019-03-11 | 2020-09-17 | Collaborative Medicinal Development, Llc | Heteroaromatic and heterobicyclic aromatic derivatives for the treatment of ferroptosis-related disorders |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
CN116283758A (zh) * | 2023-03-30 | 2023-06-23 | 安徽工业大学 | 一种喹啉合成n-甲酰基四氢喹啉的方法及产品 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ECSP003637A (es) * | 1999-08-31 | 2002-03-25 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas |
MXPA03000753A (es) * | 2000-08-08 | 2003-10-15 | Sanofi Synthelabo | Derivados de benzimidazola, su preparacion y su aplicacion terapeutica. |
WO2002044183A2 (en) * | 2000-12-01 | 2002-06-06 | Guilford Pharmaceuticals Inc. | Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors |
-
2006
- 2006-07-21 CA CA002616020A patent/CA2616020A1/en not_active Abandoned
- 2006-07-21 JP JP2008524995A patent/JP2009503069A/ja active Pending
- 2006-07-21 BR BRPI0614168A patent/BRPI0614168A2/pt not_active IP Right Cessation
- 2006-07-21 US US11/490,090 patent/US20070032469A1/en not_active Abandoned
- 2006-07-21 AU AU2006279034A patent/AU2006279034A1/en not_active Abandoned
- 2006-07-21 WO PCT/US2006/028165 patent/WO2007018998A2/en active Application Filing
- 2006-07-21 CN CNA2006800344205A patent/CN101268077A/zh active Pending
- 2006-07-21 EP EP06787957A patent/EP1912989A2/en not_active Withdrawn
- 2006-07-21 KR KR1020087001611A patent/KR20080035576A/ko not_active Application Discontinuation
- 2006-07-21 MX MX2008001152A patent/MX2008001152A/es not_active Application Discontinuation
- 2006-07-21 US US11/996,727 patent/US20080318999A1/en not_active Abandoned
- 2006-07-21 RU RU2008101923/04A patent/RU2008101923A/ru not_active Application Discontinuation
- 2006-07-24 TW TW095126927A patent/TW200745112A/zh unknown
- 2006-07-28 AR ARP060103273A patent/AR055100A1/es unknown
- 2006-07-28 UY UY29710A patent/UY29710A1/es not_active Application Discontinuation
-
2008
- 2008-01-16 IL IL188809A patent/IL188809A0/en unknown
- 2008-01-22 EC EC2008008128A patent/ECSP088128A/es unknown
- 2008-01-25 NO NO20080475A patent/NO20080475L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
RU2008101923A (ru) | 2009-09-10 |
EP1912989A2 (en) | 2008-04-23 |
KR20080035576A (ko) | 2008-04-23 |
US20080318999A1 (en) | 2008-12-25 |
AU2006279034A1 (en) | 2007-02-15 |
UY29710A1 (es) | 2007-02-28 |
CN101268077A (zh) | 2008-09-17 |
BRPI0614168A2 (pt) | 2017-07-25 |
CA2616020A1 (en) | 2007-02-15 |
US20070032469A1 (en) | 2007-02-08 |
ECSP088128A (es) | 2008-02-20 |
IL188809A0 (en) | 2008-08-07 |
WO2007018998A3 (en) | 2007-05-03 |
WO2007018998A2 (en) | 2007-02-15 |
NO20080475L (no) | 2008-04-15 |
TW200745112A (en) | 2007-12-16 |
JP2009503069A (ja) | 2009-01-29 |
MX2008001152A (es) | 2008-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR055100A1 (es) | Benzimidazoles triciclicos y su uso como moduladores de receptores metabotropicos de glutamato | |
PE20040909A1 (es) | Derivados fluoroglicosidos aromaticos con afinidad por el receptor sglt2 | |
NI200700270A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
AR058699A1 (es) | Derivados de sulfonamidoanilina como inhibidores de tirosina-quinasas jak-2 y jak-3 | |
AR049646A1 (es) | Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados | |
GT200600165A (es) | Derivados dihidrobenzofuranos y usos de los mismos | |
AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
ECSP099638A (es) | Nuevo compuesto de adenina | |
CO6220949A2 (es) | Derivados pirazolicos como inhibidores de la 11 beta -hsd1 | |
AR047966A1 (es) | Compuestos poliheterociclicos y su uso como antagonistas del receptor de glutamato metabotropico | |
CO5690548A2 (es) | N-arilheterociclos sustituidos, procedimientos para su preparacion y su empleo como medicamentos | |
PE20160548A1 (es) | Sulfonamidas como moduladores de canales de sodio | |
ECSP088871A (es) | Derivados de triazolopirazina | |
AR049398A1 (es) | Derivados de sulfamato y sulfamida; una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento util para el tratamiento de la epilepsia y trastornos relacionados. | |
AR057131A1 (es) | Derivados de purina como inmunomodulador | |
AR056645A1 (es) | Compuestos de urea sustituida inhibidores de enzimas chk1 . | |
CO5700770A2 (es) | 1,4-diazepinas sustituidas y usos de las mismas | |
ES2572263T3 (es) | Derivados de dihidrooxazina y tetrahidropirimidina como inhibidores de BACE 1 | |
AR048523A1 (es) | Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos | |
PE20071322A1 (es) | Derivados de 2-morfolinopirimidina como inhibidores de fosfatidinoinositol(pi) 3-quinasa | |
AR041508A1 (es) | Compuestos con actividad en los receptores de glutamato metabotropicos | |
AR077043A2 (es) | Pirimidinonas biciclicas y sus usos | |
CO6220853A2 (es) | Derivados de pentafluorotiobenzamido acetonitrilo como agentes antiparasitarios | |
AR110753A1 (es) | Inhibidores selectivos de jak1 | |
AR047447A1 (es) | Compuestos derivados de amino alcohol con actividad inhibidora de la renina y su uso en composiciones farmaceuticas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |